Overview

Qvar vs FP in Pediatrics

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The primary aim of this study was to compare the absolute and relative effectiveness of asthma management in paediatric patients in the UK on inhaled corticosteroid (ICS) maintenance therapy as extra-fine HFA-BDP (Qvar®) pressurised metered dose inhaler (pMDI) compared with fluticasone propionate (FP) pMDI.
Details
Lead Sponsor:
Research in Real-Life Ltd
Collaborators:
Teva Branded Pharmaceutical Products R&D, Inc.
Teva Pharmaceutical Industries
Treatments:
Beclomethasone
Fluticasone
Xhance